Gilead Sciences Inc. [GILD] Revenue clocked in at $27.52 billion, down -9.35% YTD: What’s Next?

Gilead Sciences Inc. [NASDAQ: GILD] price surged by 0.34 percent to reach at $0.22. The company report on September 16, 2022 that Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


– Positive Opinion Based on Landmark ZUMA-7 Study in Which 41% of Patients Demonstrated Event-Free Survival at Two Years versus 16% for Standard of Care -.

Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Yescarta® (axicabtagene ciloleucel) for adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. If approved, Yescarta will be the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment. Although 60% of newly diagnosed LBCL patients will respond to their initial treatment, 40% will relapse or will not respond and need 2nd line treatment.

A sum of 6140875 shares traded at recent session while its average daily volume was at 6.89M shares. Gilead Sciences Inc. shares reached a high of $65.855 and dropped to a low of $64.60 until finishing in the latest session at $65.82.

The one-year GILD stock forecast points to a potential upside of 7.01. The average equity rating for GILD stock is currently 2.60, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Gilead Sciences Inc. [GILD]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $70.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 13, 2022. While these analysts kept the previous recommendation, SVB Leerink raised their target price to Mkt Perform. The new note on the price target was released on May 23, 2022, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another drop from $75 to $65, while BMO Capital Markets kept a Market Perform rating on GILD stock. On February 02, 2022, analysts decreased their price target for GILD shares from 72 to 70.

The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.41, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 2.97. The Price to Book ratio for the last quarter was 4.09, with the Price to Cash per share for the same quarter was set at 4.56. Price to Free Cash Flow for GILD in the course of the last twelve months was 14.20 with Quick ratio for the last quarter at 1.30.

GILD Stock Performance Analysis:

Gilead Sciences Inc. [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.22. With this latest performance, GILD shares gained by 0.98% in over the last four-week period, additionally plugging by 10.77% over the last 6 months – not to mention a drop of -8.09% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 57.09, with the RSI for the last a single of trading hit 57.55, and the three-weeks RSI is set at 56.52 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 63.09, while it was recorded at 65.34 for the last single week of trading, and 63.85 for the last 200 days.

Insight into Gilead Sciences Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences Inc. [GILD] shares currently have an operating margin of +37.27 and a Gross Margin at +75.88. Gilead Sciences Inc.’s Net Margin is presently recorded at +22.74.

Return on Equity for this stock inclined to 31.70, with Return on Assets sitting at 9.13.

Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to -1.23%.

Gilead Sciences Inc. [GILD] Insider Position Details

There are presently around $65,755 million, or 82.60% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: BLACKROCK INC. with ownership of 126,937,611, which is approximately 4.296% of the company’s market cap and around 0.09% of the total institutional ownership; VANGUARD GROUP INC, holding 110,396,077 shares of the stock with an approximate value of $7.27 billion in GILD stocks shares; and STATE STREET CORP, currently with $3.81 billion in GILD stock with ownership of nearly -0.041% of the company’s market capitalization.

Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 826 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 58,873,320 shares. Additionally, 716 investors decreased positions by around 54,728,665 shares, while 194 investors held positions by with 885,411,943 shares. The mentioned changes placed institutional holdings at 999,013,928 shares, according to the latest SEC report filing. GILD stock had 134 new institutional investments in for a total of 6,348,012 shares, while 121 institutional investors sold positions of 4,968,587 shares during the same period.


Please enter your comment!
Please enter your name here